Next Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematologic Malignancies

Blood - United States
doi 10.1182/blood.v126.23.317.317
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Next-Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematological Malignancies

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2016English

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Improved Efficacy of a Next-Generation ERT in Murine Pompe Disease

JCI insight
Medicine
2019English

Hematologic Malignancies

Oncologist
Cancer ResearchMedicineOncology
1999English

Chylothorax in Hematologic Malignancies

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Vaccine Therapy in Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discovery
Oncology
2013English

In Vivo Cellular Reprogramming: The Next Generation

Cell
BiochemistryGeneticsMolecular Biology
2016English

Venous Thromboembolism in the Hematologic Malignancies

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy